| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 899-901 |
| Journal | Multiple Sclerosis |
| Volume | 18 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2012 |
Cite this
Rispens, T., Vennegoor, A., Wolbink, G. J., Polman, C. H., & Killestein, J. (2012). Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Multiple Sclerosis, 18(6), 899-901. https://doi.org/10.1177/1352458511431073
@article{798b270649b945a390a987827870ebce,
title = "Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped",
author = "T. Rispens and A. Vennegoor and G.J. Wolbink and C.H. Polman and J. Killestein",
year = "2012",
doi = "10.1177/1352458511431073",
language = "Undefined/Unknown",
volume = "18",
pages = "899--901",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",
}
Rispens, T, Vennegoor, A, Wolbink, GJ, Polman, CH & Killestein, J 2012, 'Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped' Multiple Sclerosis, vol. 18, no. 6, pp. 899-901. https://doi.org/10.1177/1352458511431073
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. / Rispens, T.; Vennegoor, A.; Wolbink, G.J.; Polman, C.H.; Killestein, J.
In: Multiple Sclerosis, Vol. 18, No. 6, 2012, p. 899-901.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped
AU - Rispens, T.
AU - Vennegoor, A.
AU - Wolbink, G.J.
AU - Polman, C.H.
AU - Killestein, J.
PY - 2012
Y1 - 2012
U2 - 10.1177/1352458511431073
DO - 10.1177/1352458511431073
M3 - Article
VL - 18
SP - 899
EP - 901
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
IS - 6
ER -